These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide. Gopal P; Grüber G; Dartois V; Dick T Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide. Krug S; Gupta M; Kumar P; Feller L; Ihms EA; Kang BG; Srikrishna G; Dawson TM; Dawson VL; Bishai WR Nat Commun; 2023 Dec; 14(1):8161. PubMed ID: 38071218 [TBL] [Abstract][Full Text] [Related]
4. Impact of immunopathology on the antituberculous activity of pyrazinamide. Blanc L; Sarathy JP; Alvarez Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Sacchettini J; Savic RM; Gengenbacher M; Podell BK; Prideaux B; Ioerger T; Dick T; Dartois V J Exp Med; 2018 Aug; 215(8):1975-1986. PubMed ID: 30018074 [TBL] [Abstract][Full Text] [Related]
5. Neutrophils express pro- and anti-inflammatory cytokines in granulomas from Mycobacterium tuberculosis-infected cynomolgus macaques. Gideon HP; Phuah J; Junecko BA; Mattila JT Mucosal Immunol; 2019 Nov; 12(6):1370-1381. PubMed ID: 31434990 [TBL] [Abstract][Full Text] [Related]
6. Antimycobacterial and healing effects of Pranlukast against MTB infection and pathogenesis in a preclinical mouse model of tuberculosis. Rajmani RS; Surolia A Front Immunol; 2024; 15():1347045. PubMed ID: 38756781 [TBL] [Abstract][Full Text] [Related]
7. Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review. Chen RH; Michael T; Kuhlin J; Schön T; Stocker S; Alffenaar JC Int J Antimicrob Agents; 2023 Sep; 62(3):106914. PubMed ID: 37419292 [TBL] [Abstract][Full Text] [Related]
9. Visualizing Pyrazinamide Action by Live Single-Cell Imaging of Phagosome Acidification and Mycobacterium tuberculosis pH Homeostasis. Santucci P; Aylan B; Botella L; Bernard EM; Bussi C; Pellegrino E; Athanasiadi N; Gutierrez MG mBio; 2022 Apr; 13(2):e0011722. PubMed ID: 35323041 [TBL] [Abstract][Full Text] [Related]
10. Hong H; Dill-McFarland KA; Simmons JD; Peterson GJ; Benchek P; Mayanja-Kizza H; Boom WH; Stein CM; Hawn TR Front Immunol; 2024; 15():1359178. PubMed ID: 38515745 [TBL] [Abstract][Full Text] [Related]
11. The expression of Nramp1 modulates the uptake of Mycobacterium tuberculosis by macrophages through alternating inflammatory responses. Meng C; Chen G; Wen D; Dong L; Cui X; Jing X; Cui J; Gao Y; Liu Y; Bu H; Wu C Tuberculosis (Edinb); 2023 Dec; 143():102414. PubMed ID: 37820457 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis. Domingo-Gonzalez R; Das S; Griffiths KL; Ahmed M; Bambouskova M; Gopal R; Gondi S; Muñoz-Torrico M; Salazar-Lezama MA; Cruz-Lagunas A; Jiménez-Álvarez L; Ramirez-Martinez G; Espinosa-Soto R; Sultana T; Lyons-Weiler J; Reinhart TA; Arcos J; de la Luz Garcia-Hernandez M; Mastrangelo MA; Al-Hammadi N; Townsend R; Balada-Llasat JM; Torrelles JB; Kaplan G; Horne W; Kolls JK; Artyomov MN; Rangel-Moreno J; Zúñiga J; Khader SA JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978810 [TBL] [Abstract][Full Text] [Related]
13. Coevolution of Fan X; Zhao B; Zhang W; Li N; Mi K; Wang B Microbiol Spectr; 2023 Aug; 11(4):e0536722. PubMed ID: 37358434 [TBL] [Abstract][Full Text] [Related]
14. A nanocompartment system contributes to defense against oxidative stress in Lien KA; Dinshaw K; Nichols RJ; Cassidy-Amstutz C; Knight M; Singh R; Eltis LD; Savage DF; Stanley SA Elife; 2021 Nov; 10():. PubMed ID: 34751132 [TBL] [Abstract][Full Text] [Related]
15. Ferritin H Deficiency in Myeloid Compartments Dysregulates Host Energy Metabolism and Increases Susceptibility to Reddy VP; Chinta KC; Saini V; Glasgow JN; Hull TD; Traylor A; Rey-Stolle F; Soares MP; Madansein R; Rahman MA; Barbas C; Nargan K; Naidoo T; Ramdial PK; George JF; Agarwal A; Steyn AJC Front Immunol; 2018; 9():860. PubMed ID: 29774023 [TBL] [Abstract][Full Text] [Related]
16. Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities. Zhang X; Xie Q; Ye Z; Li Y; Che Z; Huang M; Zeng J Front Immunol; 2021; 12():695278. PubMed ID: 34367155 [TBL] [Abstract][Full Text] [Related]
17. Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis. Krug S; Parveen S; Bishai WR Front Immunol; 2021; 12():660916. PubMed ID: 33953722 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of leukotriene-B4 signalling-mediated host response to tuberculosis is a potential mode of adjunctive host-directed therapy. Banerjee U; Borbora SM; Guha M; Yadav V; Sanjay V; Singh A; Balaji KN; Chandra N Immunology; 2024 Jul; 172(3):392-407. PubMed ID: 38504502 [TBL] [Abstract][Full Text] [Related]
19. Identification of a Diagnostic Multiomics-Based Biomarker Cluster in a Mouse Model of Pulmonary Tuberculosis. Zhang H; Shi M; Yu L; Ran F; Zheng N; Wang X; Liu Y; Li C; Li D; Li J; Bi L; Wu Z Discov Med; 2024 Jun; 36(185):1268-1279. PubMed ID: 38926113 [TBL] [Abstract][Full Text] [Related]
20. Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets. Reichmann MT; Tezera LB; Vallejo AF; Vukmirovic M; Xiao R; Reynolds J; Jogai S; Wilson S; Marshall B; Jones MG; Leslie A; D'Armiento JM; Kaminski N; Polak ME; Elkington P J Clin Invest; 2021 Aug; 131(15):. PubMed ID: 34128839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]